Summary
Final overall survival and safety results of the phase 3 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor trial [RADIANT-3; NCT00412061] have bolstered previous findings that everolimus is effective and safe in the treatment of advanced pancreatic neuroendocrine tumors.
- Soft Tissue Cancers
- Oncology Clinical Trials
- Neuroendocrine Tumors
- Soft Tissue Cancers
- Oncology Clinical Trials
- Oncology
- Neuroendocrine Tumors
- © 2014 MD Conference Express®
Tools
Everolimus Safe and Effective for Advanced pNET: Final Results of RADIANT-3
Permalink:
Table of contents
Cited By...
- No citing articles found.